Metrigen

Metrigen is a branded hormone replacement therapy product historically marketed by Merck (MSD) and later included in a portfolio of 11 branded finished-dose molecules whose rights were optioned by Aspen Pharmacare. Publicly available transaction documents consistently list Metrigen alongside other hormone replacement therapies such as Ovestin and Sustanon, indicating that it is an HRT preparation, but do not disclose its precise active ingredient(s), formulation, or detailed pharmacology. As a result, while it can be characterized at a high level as a hormone replacement therapy pharmaceutical, its specific molecular mechanism of action, receptor targets, and detailed clinical profile cannot be reliably specified from accessible sources.

Brand names

Metrigen